FAIR ACT

[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [H.R. 7953 Introduced in House (IH)] <DOC> 119th CONGRESS 2d Session H. R. 7953 To accelerate patient access to innovative medicines and clinical trials for life-threatening diseases by establishing a reciprocal approval mechanism with trusted international regulatory authorities. _______________________________________________________________________ IN THE HOUSE OF REPRESENTATIVES March 17, 2026 Mr. Sessions (for himself and Mr. Peters) introduced the following bill; which was referred to the Committee on Energy and Commerce _______________________________________________________________________ A BILL To accelerate patient access to innovative medicines and clinical trials for life-threatening diseases by establishing a reciprocal approval mechanism with trusted international regulatory authorities. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the ``Fast-tracking Approval for Innovative Rare disease therapies Act'' or the ``FAIR ACT''. SEC. 2. FINDINGS. Congress finds the following: (1) Patients in the United States often face significant delays in accessing innovative medicines compared to patients in other trusted nations. (2) The lengthy regulatory process at the Food and Drug Administration contributes to the movement of clinical trials abroad, leading to fewer opportunities for United States patients to participate in cutting-edge research. (3) China and other nations are rapidly expanding their clinical trial and biopharmaceutical development capacity, threatening United States leadership in biomedical innovation. (4) A reciprocal approval mechanism with trusted international regulatory authorities will accelerate access for United States patients to life-saving therapies and preserve the United States competitive position in biomedical research and innovation. S